The transcription factors TBX2 and TBX3 interact with human papillomavirus 16 (HPV16) L2 and repress the long control region of HPVs

Journal of Virology

Volumn 87, Issue 8, 2013, Pages 4461-4474

  Schneider, Marc A ^a   Scheffer, Konstanze D ^a   Bund, Timo ^a,c   Boukhallouk, Fatima ^a   Lambert, Carsten ^a   Cotarelo, Cristina ^a   Pflugfelder, Gert O ^b   Florin, Luise ^a   Spoden, Gilles A ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c MAX PLANCK INSTITUTE FOR POLYMER RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TBX2; TRANSCRIPTION FACTOR TBX3; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN L2;

ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE REPRESSION; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; LONG CONTROL REGION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SCREENING TEST; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

CAPSID PROTEINS; HELA CELLS; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOPRECIPITATION; MICROSCOPY, FLUORESCENCE; ONCOGENE PROTEINS, VIRAL; PROTEIN INTERACTION MAPPING; T-BOX DOMAIN PROTEINS; TRANSCRIPTION, GENETIC; TWO-HYBRID SYSTEM TECHNIQUES; VIRUS REPLICATION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16; MIRIDAE; PAPILLOMAVIRIDAE;

EID: 84875774515     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01803-12     Document Type: Article

References (86)

1. Howley PM, Lowy DR. 2007. Papillomaviruses, p 2299-2354. In Knipe DM, Howley PM (ed), Fields virology, 5th ed. Lippincott, Williams & Wilkins, Philadelphia, PA.
2. Laimins LA. 1993. The biology of human papillomaviruses: from warts to cancer. Infect. Agents Dis. 2:74-86.
3. zur Hausen H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer. 2:342-350.
4. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. 1991. Structures of bovine and human papillomaviruses. Analysis by cryo-electron microscopy and three-dimensional image reconstruction. Biophys. J. 60:1445-1456.
5. Modis Y, Trus BL, Harrison SC. 2002. Atomic model of the papillomavirus capsid. EMBO J. 21:4754-4762.
6. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL. 2008. Arrangement of L2 within the papillomavirus capsid. J. Virol. 82:5190-5197.
7. Kamper N, Day PM, Nowak T, Selinka HC, Florin L, Bolscher J, Hilbig L, Schiller JT, Sapp M. 2006. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J. Virol. 80:759-768.
8. Florin L, Becker KA, Lambert C, Nowak T, Sapp C, Strand D, Streeck RE, Sapp M. 2006. Identification of a dynein interacting domain in the papillomavirus minor capsid protein l2. J. Virol. 80:6691-6696.
9. Florin L, Sapp M, Spoden GA. 2012. Host-cell factors involved in papillomavirus entry. Med. Microbiol. Immunol. 201:437-448.
10. Schneider MA, Spoden GA, Florin L, Lambert C. 2011. Identification of the dynein light chains required for human papillomavirus infection. Cell Microbiol. 13:32-46.
11. Day PM, Baker CC, Lowy DR, Schiller JT. 2004. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc. Natl. Acad. Sci. U. S. A. 101:14252-14257.
12. Baldwin A, Hypes MK, Pirisi L, Creek KE. 2007. NFI is an essential positive transcription factor for human papillomavirus type 16 early gene expression. Open Virol. J. 1:33-38.
13. Chong T, Apt D, Gloss B, Isa M, Bernard HU. 1991. The enhancer of human papillomavirus type 16: binding sites for the ubiquitous transcription factors oct-1, NFA, TEF-2, NF1, and AP-1 participate in epithelial cell-specific transcription. J. Virol. 65:5933-5943.
14. Chong T, Chan WK, Bernard HU. 1990. Transcriptional activation of human papillomavirus 16 by nuclear factor I, AP1, steroid receptors and a possibly novel transcription factor, PVF: a model for the composition of genital papillomavirus enhancers. Nucleic Acids Res. 18:465-470.
15. Cripe TP, Haugen TH, Turk JP, Tabatabai F, Schmid PG, III, Durst M, Gissmann L, Roman A, Turek LP. 1987. Transcriptional regulation of the human papillomavirus-16 E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-activator and repressor gene products: implications for cervical carcinogenesis. EMBO J. 6:3745-3753.
16. Dollard SC, Broker TR, Chow LT. 1993. Regulation of the human papillomavirus type 11 E6 promoter by viral and host transcription factors in primary human keratinocytes. J. Virol. 67:1721-1726.
17. Garcia-Carranca A, Thierry F, Yaniv M. 1988. Interplay of viral and cellular proteins along the long control region of human papillomavirus type 18. J. Virol. 62:4321-4330.
18. Ishiji T, Lace MJ, Parkkinen S, Anderson RD, Haugen TH, Cripe TP, Xiao JH, Davidson I, Chambon P, Turek LP. 1992. Transcriptional enhancer factor (TEF)-1 and its cell-specific co-activator activate human papillomavirus-16 E6 and E7 oncogene transcription in keratinocytes and cervical carcinoma cells. EMBO J. 11:2271-2281.
19. Kukimoto I, Takeuchi T, Kanda T. 2006. CCAAT/enhancer binding protein beta binds to and activates the P670 promoter of human papillomavirus type 16. Virology 346:98-107.
20. Kyo S, Inoue M, Nishio Y, Nakanishi K, Akira S, Inoue H, Yutsudo M, Tanizawa O, Hakura A. 1993. NF-IL6 represses early gene expression of human papillomavirus type 16 through binding to the noncoding region. J. Virol. 67:1058-1066.
21. Thierry F, Spyrou G, Yaniv M, Howley P. 1992. Two AP1 sites binding JunB are essential for human papillomavirus type 18 transcription in keratinocytes. J. Virol. 66:3740-3748.
22. Doorbar J. 2006. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. 110:525-541.
23. Lee C, Laimins LA. 2007. The differentiation-dependent life cycle of human papillomaviruses in keratinocytes, p 45-67. In Garcea RL, DiMaio D (ed), The papillomaviruses. Springer Science and Business Media, New York, NY.
24. del Mar Pena LM, Laimins LA. 2001. Differentiation-dependent chromatin rearrangement coincides with activation of human papillomavirus type 31 late gene expression. J. Virol. 75:10005-10013.
25. Grassmann K, Rapp B, Maschek H, Petry KU, Iftner T. 1996. Identification of a differentiation-inducible promoter in the E7 open reading frame of human papillomavirus type 16 (HPV-16) in raft cultures of a new cell line containing high copy numbers of episomal HPV-16 DNA. J. Virol. 70:2339-2349.
26. Hummel M, Hudson JB, Laimins LA. 1992. Differentiation-induced and constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes. J. Virol. 66:6070-6080.
27. Day PM, Roden RB, Lowy DR, Schiller JT. 1998. The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J. Virol. 72:142-150.
28. Florin L, Schafer F, Sotlar K, Streeck RE, Sapp M. 2002. Reorganization of nuclear domain 10 induced by papillomavirus capsid protein L2. Virology 295:97-107.
29. Okun MM, Day PM, Greenstone HL, Booy FP, Lowy DR, Schiller JT, Roden RB. 2001. L1 interaction domains of papillomavirus L2 necessary for viral genome encapsidation. J. Virol. 75:4332-4342.
30. Stauffer Y, Raj K, Masternak K, Beard P. 1998. Infectious human papillomavirus type 18 pseudovirions. J. Mol. Biol. 283:529-536.
31. Zhao KN, Sun XY, Frazer IH, Zhou J. 1998. DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 243: 482-491.
32. Kispert A, Hermann BG. 1993. The Brachyury gene encodes a novel DNA binding protein. EMBO J. 12:4898-4899.
33. Tada M, Smith JC. 2001. T-targets: clues to understanding the functions of T-box proteins. Dev. Growth Differ. 43:1-11.
34. Wilson V, Conlon FL. 2002. The T-box family. Genome Biol. 3: REVIEWS3008. doi:10.1186/gb-2002-3-6-reviews3008.
35. Smith J. 1999. T-box genes: what they do and how they do it. Trends Genet. 15:154-158.
36. Carreira S, Dexter TJ, Yavuzer U, Easty DJ, Goding CR. 1998. Brachyury-related transcription factor Tbx2 and repression of the melanocyte- specific TRP-1 promoter. Mol. Cell. Biol. 18:5099-5108.
37. He M, Wen L, Campbell CE, Wu JY, Rao Y. 1999. Transcription repression by Xenopus ET and its human ortholog TBX3, a gene involved in ulnar-mammary syndrome. Proc. Natl. Acad. Sci. U. S. A. 96:10212-10217.
38. King M, Arnold JS, Shanske A, Morrow BE. 2006. T-genes and limb bud development. Am. J. Med. Genet. A 140:1407-1413.
39. Plageman TF, Jr, Yutzey KE. 2005. T-box genes and heart development: putting the "T" in heart. Dev. Dyn. 232:11-20.
40. Rowley M, Grothey E, Couch FJ. 2004. The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. J. Mammary Gland Biol. Neoplasia 9:109-118.
41. Bamshad M, Lin RC, Law DJ, Watkins WC, Krakowiak PA, Moore ME, Franceschini P, Lala R, Holmes LB, Gebuhr TC, Bruneau BG, Schinzel A, Seidman JG, Seidman CE, Jorde LB. 1997. Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. Nat. Genet. 16:311-315.
42. Lu J, Li XP, Dong Q, Kung HF, He ML. 2010. TBX2 and TBX3: the special value for anticancer drug targets. Biochim. Biophys. Acta 1806: 268-274.
43. Carlson H, Ota S, Campbell CE, Hurlin PJ. 2001. A dominant repression domain in Tbx3 mediates transcriptional repression and cell immortalization: relevance to mutations in Tbx3 that cause ulnar-mammary syndrome. Hum. Mol. Genet. 10:2403-2413.
44. Jacobs JJ, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM, van Welsem T, van de Vijver MJ, Koh EY, Daley GQ, van Lohuizen M. 2000. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet. 26:291-299.
45. Yarosh W, Barrientos T, Esmailpour T, Lin L, Carpenter PM, Osann K, Anton-Culver H, Huang T. 2008. TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases. Cancer Res. 68:693-699.
46. Prince S, Carreira S, Vance KW, Abrahams A, Goding CR. 2004. Tbx2 directly represses the expression of the p21(WAF1) cyclin-dependent kinase inhibitor. Cancer Res. 64:1669-1674.
47. Chen JR, Chatterjee B, Meyer R, Yu JC, Borke JL, Isales CM, Kirby ML, Lo CW, Bollag RJ. 2004. Tbx2 represses expression of Connexin43 in osteoblastic-like cells. Calcif. Tissue Int. 74:561-573.
48. Redmond KL, Crawford NT, Farmer H, D'Costa ZC, O'Brien GJ, Buckley NE, Kennedy RD, Johnston PG, Harkin DP, Mullan PB. 2010. T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells. Oncogene 29:3252-3262.
49. Rodriguez M, Aladowicz E, Lanfrancone L, Goding CR. 2008. Tbx3represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res. 68:7872-7881.
50. Vance KW, Shaw HM, Rodriguez M, Ott S, Goding CR. 2010. The retinoblastoma protein modulates Tbx2 functional specificity. Mol. Biol. Cell 21:2770-2779.
51. Leder C, Kleinschmidt JA, Wiethe C, Muller M. 2001. Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J. Virol. 75:9201-9209.
52. Schweiger MR, Ottinger M, You J, Howley PM. 2007. Brd4-independent transcriptional repression function of the papillomavirus e2 proteins. J. Virol. 81:9612-9622.
53. Volpers C, Sapp M, Snijders PJ, Walboomers JM, Streeck RE. 1995. Conformational and linear epitopes on virus-like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2. J. Gen. Virol. 76:2661-2667.
54. Rommel O, Dillner J, Fligge C, Bergsdorf C, Wang X, Selinka HC, Sapp M. 2005. Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA. J. Med. Virol. 75:114-121.
55. Gyuris J, Golemis E, Chertkov H, Brent R. 1993. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 75:791-803.
56. Vance KW, Carreira S, Brosch G, Goding CR. 2005. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res. 65:2260-2268.
57. Florin L, Sapp C, Streeck RE, Sapp M. 2002. Assembly and translocation of papillomavirus capsid proteins. J. Virol. 76:10009-10014.
58. Lin Z, Yemelyanova AV, Gambhira R, Jagu S, Meyers C, Kirnbauer R, Ronnett BM, Gravitt PE, Roden RB. 2009. Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am. J. Pathol. 174:136-143.
59. Baldwin A, Pirisi L, Creek KE. 2004. NFI-Ski interactions mediate transforming growth factor beta modulation of human papillomavirus type 16 early gene expression. J. Virol. 78:3953-3964.
60. Kang YH, Kang M-J, Paik SG, Park SN, Yoon D-Y. 2003. Repression of HPV E6-activated RSV promoter activity by anti-cancer agents. Antiviral Res. 58:65-71.
61. Lingbeek ME, Jacobs JJ, van Lohuizen M. 2002. The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator. J. Biol. Chem. 277:26120-26127.
62. Sinha S, Abraham S, Gronostajski RM, Campbell CE. 2000. Differential DNA binding and transcription modulation by three T-box proteins, T, TBX1 and TBX2. Gene 258:15-29.
63. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. 1997. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J. 16:504-514.
64. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur Hausen H. 1985. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314:111-114.
65. Heino P, Zhou J, Lambert PF. 2000. Interaction of the papillomavirus transcription/replication factor, E2, and the viral capsid protein, L2. Virology 276:304-314.
66. Okoye A, Cordano P, Taylor ER, Morgan IM, Everett R, Campo MS. 2005. Human papillomavirus 16 L2 inhibits the transcriptional activation function, but not the DNA replication function, of HPV-16 E2. Virus Res. 108:1-14.
67. Schreiner S, Martinez R, Groitl P, Rayne F, Vaillant R, Wimmer P, Bossis G, Sternsdorf T, Marcinowski L, Ruzsics Z, Dobner T, Wodrich H. 2012. Transcriptional activation of the adenoviral genome is mediated by capsid protein VI. PLoS Pathog. 8:e1002549. doi:10.1371/journal.ppat .1002549.
68. Florin L, Becker KA, Sapp C, Lambert C, Sirma H, Muller M, Streeck RE, Sapp M. 2004. Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70. J. Virol. 78:5546-5553.
69. Gornemann J, Hofmann TG, Will H, Muller M. 2002. Interaction of human papillomavirus type 16 L2 with cellular proteins: identification of novel nuclear body-associated proteins. Virology 303:69-78.
70. Fedele M, Benvenuto G, Pero R, Majello B, Battista S, Lembo F, Vollono E, Day PM, Santoro M, Lania L, Bruni CB, Fusco A, Chiariotti L. 2000. A novel member of the BTB/POZ family, PATZ, associates with the RNF4 RING finger protein and acts as a transcriptional repressor. J. Biol. Chem. 275:7894-7901.
71. Bilican B, Goding CR. 2006. Cell cycle regulation of the T-box transcription factor tbx2. Exp. Cell Res. 312:2358-2366.
72. Martin N, Benhamed M, Nacerddine K, Demarque MD, van Lohuizen M, Dejean A, Bischof O. 2012. Physical and functional interaction between PML and TBX2 in the establishment of cellular senescence. EMBO J. 31:95-109.
73. Zhou J, Sun XY, Louis K, Frazer IH. 1994. Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence. J. Virol. 68:619-625.
74. Dowhanick JJ, McBride AA, Howley PM. 1995. Suppression of cellular proliferation by the papillomavirus E2 protein. J. Virol. 69:7791-7799.
75. Goodwin EC, Yang E, Lee CJ, Lee HW, DiMaio D, Hwang ES. 2000. Rapid induction of senescence in human cervical carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 97:10978-10983.
76. Hall AH, Alexander KA. 2003. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J. Virol. 77:6066-6069.
77. Lea JS, Sunaga N, Sato M, Kalahasti G, Miller DS, Minna JD, Muller CY. 2007. Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells. Reprod. Sci. 14:20-28.
78. Nauenburg S, Zwerschke W, Jansen-Durr P. 2001. Induction of apoptosis in cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7 oncoprotein. FASEB J. 15:592-594.
79. Nishimura A, Ono T, Ishimoto A, Dowhanick JJ, Frizzell MA, Howley PM, Sakai H. 2000. Mechanisms of human papillomavirus E2-mediated repression of viral oncogene expression and cervical cancer cell growth inhibition. J. Virol. 74:3752-3760.
80. Wells SI, Francis DA, Karpova AY, Dowhanick JJ, Benson JD, Howley PM. 2000. Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways. EMBO J. 19:5762-5771.
81. Morandell D, Kaiser A, Herold S, Rostek U, Lechner S, Mitterberger MC, Jansen-Durr P, Eilers M, Zwerschke W. 2012. The human papillomavirus type 16 E7 oncoprotein targets Myc-interacting zinc-finger protein- 1. Virology 422:242-253.
82. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. 2012. The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl. 5):F55-F70.
83. Isaacson Wechsler E, Wang Q, Roberts I, Pagliarulo E, Jackson D, Untersperger C, Coleman N, Griffin H, Doorbar J. 2012. Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression. J. Virol. 86:6358-6364.
84. Middleton K, Peh W, Southern S, Griffin H, Sotlar K, Nakahara T, El-Sherif A, Morris L, Seth R, Hibma M, Jenkins D, Lambert P, Coleman N, Doorbar J. 2003. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J. Virol. 77:10186-10201.
85. Hansen CN, Nielsen L, Norrild B. 2010. Activities of E7 promoters in the human papillomavirus type 16 genome during cell differentiation. Virus Res. 150:34-42.
86. Holmgren SC, Patterson NA, Ozbun MA, Lambert PF. 2005. The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. J. Virol. 79:3938-3948.